home · filing · 0001193125-23-035908
8-K filed February 13, 2023, 6:59 PM ET
ticker VIR
CIK 0001706431
other material
confidence high
sentiment neutral
materiality 0.60
Vir Bio amends GSK deal: regains full rights to vaccine program, narrows antibody program
Vir Biotechnology, Inc.
Amendments remove CoV Vaccine Program from collaboration; Vir retains rights to progress independently.
CoV Antibody Program narrowed to only sotrovimab and VIR-7832; all other antibodies revert to Vir.
Vir pays tiered royalties in low single digits on vaccine sales, low-to-mid single digits on terminated antibodies.
Amendments effective March 31, 2022 (vaccine wind-down) and February 8, 2023 (antibody scope reduction).
GSK retains 50:50 profit share on sotrovimab and VIR-7832 under original DCA terms.
Key facts
Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Vir Biotechnology, Inc. entered into Amendment No. 2 and Amendment No. 3 to the DCA with GSK (effective 2023-02-08).
Action entry
Agreement collaboration
Counterparty GSK
Effective 2023-02-08
Exact text from the filing
On February 8, 2023, the Company, and GSK entered into Amendment No. 2 and Amendment No. 3 to the DCA (collectively, the “DCA Amendments”).
View on SEC.gov
Source: SEC EDGAR
accession 0001193125-23-035908
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.